Astex and MMRC commence Stage II clinical trial of AT7519 CDK inhibitor in multiple myeloma Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Stage II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to take care of patients with refractory or relapsed multiple myeloma, an incurable blood malignancy. This clinical trial will be conducted through MMRC Member Institution others and sites in the USA. ‘Continuing our romantic relationship with Astex in the advancement of AT7519 confirms the effectiveness of our end-to-end drug development model, including identifying promising drug candidates, funding early analysis and injecting efficiency into the development procedure,’ said Kathy Giusti, CEO and Founder of the MMRF and MMRC.The WBB survey says if bird flu impacts human beings at the same degree of virulence as the existing H5N1 strain, virtually all sufferers would need hospitalization, which would create a shortage of some 6.5 million hospital beds each day during the pandemic. It provides that police also, fire, sanitation and additional critical providers will become strained with brief overtime and staff function, which would effect on municipal and condition budgets. The record also warns of the chance of civil disturbances due to individuals who either believe they are able to make use of the circumstance or who experience they have little potential for survival so they could as well appreciate themselves while they are able to.